vs
Healthpeak Properties（DOC）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
Healthpeak Properties的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.9倍（$719.4M vs $373.9M），Healthpeak Properties净利率更高（73.2% vs 7.3%，领先65.8%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 8.9%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
DOC vs PAHC — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $373.9M |
| 净利润 | $114.0M | $27.5M |
| 毛利率 | — | 35.5% |
| 营业利润率 | 17.4% | 13.5% |
| 净利率 | 73.2% | 7.3% |
| 营收同比 | 3.1% | 20.9% |
| 净利润同比 | 2406.4% | 762.1% |
| 每股收益（稀释后） | $0.16 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $719.4M | $373.9M | ||
| Q3 25 | $705.9M | $363.9M | ||
| Q2 25 | $694.3M | $378.7M | ||
| Q1 25 | $702.9M | $347.8M | ||
| Q4 24 | $698.0M | $309.3M | ||
| Q3 24 | $700.4M | $260.4M | ||
| Q2 24 | $695.5M | $273.2M | ||
| Q1 24 | $606.6M | $263.2M |
| Q4 25 | $114.0M | $27.5M | ||
| Q3 25 | $-117.1M | $26.5M | ||
| Q2 25 | $31.7M | $17.2M | ||
| Q1 25 | $42.8M | $20.9M | ||
| Q4 24 | $4.5M | $3.2M | ||
| Q3 24 | $85.9M | $7.0M | ||
| Q2 24 | $146.0M | $752.0K | ||
| Q1 24 | $6.7M | $8.4M |
| Q4 25 | — | 35.5% | ||
| Q3 25 | 58.6% | 32.9% | ||
| Q2 25 | 60.2% | 29.0% | ||
| Q1 25 | 61.1% | 30.1% | ||
| Q4 24 | 60.3% | 32.9% | ||
| Q3 24 | 60.0% | 32.1% | ||
| Q2 24 | 60.6% | 31.9% | ||
| Q1 24 | 59.8% | 30.2% |
| Q4 25 | 17.4% | 13.5% | ||
| Q3 25 | 9.2% | 14.1% | ||
| Q2 25 | 5.7% | 8.9% | ||
| Q1 25 | 7.7% | 9.6% | ||
| Q4 24 | -2.2% | 8.3% | ||
| Q3 24 | 14.1% | 6.8% | ||
| Q2 24 | 22.3% | 6.7% | ||
| Q1 24 | 3.7% | 7.6% |
| Q4 25 | 73.2% | 7.3% | ||
| Q3 25 | -16.6% | 7.3% | ||
| Q2 25 | 4.6% | 4.5% | ||
| Q1 25 | 6.1% | 6.0% | ||
| Q4 24 | 0.7% | 1.0% | ||
| Q3 24 | 12.3% | 2.7% | ||
| Q2 24 | 21.0% | 0.3% | ||
| Q1 24 | 1.1% | 3.2% |
| Q4 25 | $0.16 | $0.67 | ||
| Q3 25 | $-0.17 | $0.65 | ||
| Q2 25 | $0.05 | $0.43 | ||
| Q1 25 | $0.06 | $0.51 | ||
| Q4 24 | $0.02 | $0.08 | ||
| Q3 24 | $0.12 | $0.17 | ||
| Q2 24 | $0.21 | $0.02 | ||
| Q1 24 | $0.01 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $74.5M |
| 总债务越低越好 | $9.8B | $624.2M |
| 股东权益账面价值 | $7.5B | $332.4M |
| 总资产 | $20.3B | $1.4B |
| 负债/权益比越低杠杆越低 | 1.31× | 1.88× |
8季度趋势，按日历期对齐
| Q4 25 | $467.5M | $74.5M | ||
| Q3 25 | $91.0M | $85.3M | ||
| Q2 25 | $89.4M | $77.0M | ||
| Q1 25 | $70.6M | $70.4M | ||
| Q4 24 | $119.8M | $67.1M | ||
| Q3 24 | $180.4M | $89.8M | ||
| Q2 24 | $106.9M | $114.6M | ||
| Q1 24 | $101.8M | $98.7M |
| Q4 25 | $9.8B | $624.2M | ||
| Q3 25 | $9.1B | $628.0M | ||
| Q2 25 | $9.0B | $631.7M | ||
| Q1 25 | $8.9B | $635.4M | ||
| Q4 24 | $8.7B | $639.1M | ||
| Q3 24 | $8.6B | $295.2M | ||
| Q2 24 | $8.6B | $312.1M | ||
| Q1 24 | $8.8B | — |
| Q4 25 | $7.5B | $332.4M | ||
| Q3 25 | $7.6B | $311.7M | ||
| Q2 25 | $7.9B | $285.7M | ||
| Q1 25 | $8.2B | $266.0M | ||
| Q4 24 | $8.4B | $246.8M | ||
| Q3 24 | $8.6B | $258.5M | ||
| Q2 24 | $8.8B | $256.6M | ||
| Q1 24 | $8.9B | $270.1M |
| Q4 25 | $20.3B | $1.4B | ||
| Q3 25 | $19.6B | $1.4B | ||
| Q2 25 | $19.8B | $1.4B | ||
| Q1 25 | $19.8B | $1.3B | ||
| Q4 24 | $19.9B | $1.3B | ||
| Q3 24 | $20.0B | $966.3M | ||
| Q2 24 | $20.2B | $982.2M | ||
| Q1 24 | $20.5B | $979.0M |
| Q4 25 | 1.31× | 1.88× | ||
| Q3 25 | 1.20× | 2.01× | ||
| Q2 25 | 1.14× | 2.21× | ||
| Q1 25 | 1.08× | 2.39× | ||
| Q4 24 | 1.04× | 2.59× | ||
| Q3 24 | 1.00× | 1.14× | ||
| Q2 24 | 0.98× | 1.22× | ||
| Q1 24 | 0.99× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $8.3M |
| 自由现金流率自由现金流/营收 | 49.6% | 2.2% |
| 资本支出强度资本支出/营收 | 124.4% | 3.0% |
| 现金转化率经营现金流/净利润 | 10.99× | 0.70× |
| 过去12个月自由现金流最近4个季度 | — | $47.3M |
8季度趋势，按日历期对齐
| Q4 25 | $1.3B | $19.4M | ||
| Q3 25 | $315.0M | $9.3M | ||
| Q2 25 | $363.5M | $21.3M | ||
| Q1 25 | $279.4M | $43.2M | ||
| Q4 24 | $1.1B | $3.1M | ||
| Q3 24 | $318.2M | $12.6M | ||
| Q2 24 | $316.2M | $28.4M | ||
| Q1 24 | $152.6M | $11.4M |
| Q4 25 | $357.0M | $8.3M | ||
| Q3 25 | — | $-4.5M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $35.4M | ||
| Q4 24 | $333.7M | $-4.7M | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | — | $15.4M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | 49.6% | 2.2% | ||
| Q3 25 | — | -1.2% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | 47.8% | -1.5% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | 124.4% | 3.0% | ||
| Q3 25 | — | 3.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | 105.6% | 2.5% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 4.8% | ||
| Q1 24 | — | 3.7% |
| Q4 25 | 10.99× | 0.70× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | 11.48× | 1.24× | ||
| Q1 25 | 6.52× | 2.07× | ||
| Q4 24 | 235.43× | 0.97× | ||
| Q3 24 | 3.71× | 1.81× | ||
| Q2 24 | 2.17× | 37.80× | ||
| Q1 24 | 22.85× | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
